

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

1.3.1 Summary Product Characteristics

1. Name of the proprietary product:

Name of the nonproprietary International Product: Pentazocine Injection BP 30 mg, 1 mL Ampoule

Route of Administration: IV/IM/SC

2. Qualitative and Quantitative

composition: Batch size: 100 Ltr

Sr. No.	Ingredient	Grade	Label Claim Each ml (mg/mL)	Overages	Std. Qty. (kg/Ltr)	Function
1.	Pentazocine Lactate	BP	30.0	-	3.0*	Active ingredient
2.	Lactic Acid	BP	15.00	-	1.5	Antibacterial
3.	Benzyl Alcohol	USP	1.5%v/v	-	1.5*	Preservatives
4.	Sodium Chloride	BP	2.800	-	0.28	Tonicity agent
5.	Sodium Hydroxide Pellets	BP	0.800	-	0.08	pH adjusting
6.	Water for Injections	BP	Q.S to 1.0 mL	-	Q.S. to 100 Ltr	Solvent

* The Quantity of pentazocine indicated is based on assay as 100% consideration, Potency calculation is to be done while dispensing considering the actual assay.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

3. Pharmaceutical Form: Sterile solution for injection

4. Clinical Particulars

4.1 Therapeutic indications

VALUELIFE is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. VALUELIFE may also be used for preoperative or preanesthetic medication and as a supplement to surgical anesthesia.

Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve VALUELIFE for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

- Have not been tolerated, or are not expected to be tolerated,
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

4.2 Posology and method of administration

Important Dosage and Administration Instructions

Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.

Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse.

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with VALUELIFE and adjust the dosage accordingly.

Do not mix VALUELIFE in the same syringe with soluble barbiturates because precipitation will occur.

Initial Dosage

Adults, Excluding Patients in Labor

The recommended single parenteral dose is 30 mg by intramuscular, subcutaneous, or intravenous route. This may be repeated every 3 to 4 hours. Doses in excess of 30 mg intravenously or 60 mg intramuscularly or subcutaneously are not recommended. Total daily dosage should not exceed 360 mg. Elderly patients may be more sensitive to the analgesic effects of VALUELIFE than younger patients. Elderly patients generally should be started on low doses of VALUELIFE and observed closely. The subcutaneous route of administration should be used only when necessary because of possible severe tissue damage at injection sites. When frequent injections are needed, the drug should be administered intramuscularly. In addition, constant rotation of injection sites (e.g., the upper outer quadrants of the buttocks, mid-lateral aspects of the thighs, and the deltoid areas) is essential.

Patients in Labor

A single, intramuscular 30 mg dose has been most commonly administered. An intravenous 20 mg dose has given adequate pain relief to some patients in labor when contractions become regular, and this dose may be given two or three times at two- to three-hour intervals, as needed.

Excluding Patients Less Than One Year Old

The recommended single parenteral dose as premedication for sedation is 0.5 mg/kg by intramuscular route

CAUTION: VALUELIFE should not be mixed in the same syringe with soluble barbiturates because precipitation will occur.

Initiating Treatment with VALUELIFE

There is inter-patient variability in the potency of opioid drugs and opioid formulations.

Therefore, a conservative approach is advised when determining the total daily dosage of VALUELIFE. It is safer to underestimate a patient's 24-hour VALUELIFE dosage than to overestimate the 24-hour VALUELIFE dosage and manage an adverse reaction due to overdose.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

Titration and Maintenance of Therapy

Individually titrate VALUELIFE to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving VALUELIFE to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the VALUELIFE dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Discontinuation of VALUELIFE

When a patient who has been taking VALUELIFE regularly and may be physically dependent no longer requires therapy with VALUELIFE, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue VALUELIFE in a physically-dependent patient.

4.3 Contraindications

VALUELIFE is contraindicated in patients with:

- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to pentazocine (e.g., anaphylaxis)

4.4 Special warnings and precautions for use

Addiction, Abuse, and Misuse

VALUELIFE contains pentazocine, a Schedule IV controlled substance. As an opioid, VALUELIFE exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed VALUELIFE. Addiction can occur at recommended dosages and if the drug is misused or abused. Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing VALUELIFE, and monitor all patients receiving VALUELIFE for the development of these behaviors or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as VALUELIFE, but use in such patients necessitates intensive counseling about the risks and proper use of VALUELIFE along with intensive monitoring for signs of addiction, abuse, and misuse. Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing VALUELIFE. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status. Carbon dioxide (CO₂) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of VALUELIFE, the risk is greatest

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases of VALUELIFE. To reduce the risk of respiratory depression, proper dosing and titration of VALUELIFE are essential. Overestimating the VALUELIFE dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of VALUELIFE during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of VALUELIFE Injection with benzodiazepines or other CNS depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics. If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation.

Advise both patients and caregivers about the risks of respiratory depression and sedation when VALUELIFE Injection is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drug.

Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients

The use of VALUELIFE in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease: VALUELIFE -treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of VALUELIFE.

Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.

Monitor such patients closely, particularly when initiating and titrating VALUELIFE and when VALUELIFE is given concomitantly with other drugs that depress respiration. Alternatively, consider the use of non-opioid analgesics in these patients.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

Adrenal Insufficiency

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Severe Hypotension

VALUELIFE may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dosage of VALUELIFE. In patients with circulatory shock, VALUELIFE may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of VALUELIFE in patients with circulatory shock.

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness

In patients who may be susceptible to the intracranial effects of CO₂ retention (e.g., those with evidence of increased intracranial pressure or brain tumors), VALUELIFE may reduce respiratory drive, and the resultant CO₂ retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with VALUELIFE. Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of VALUELIFE in patients with impaired consciousness or coma.

Risks of Use in Patients with Gastrointestinal Conditions

VALUELIFE is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus. The pentazocine in VALUELIFE may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms.

Increased Risk of Seizures in Patients with Convulsive or Seizure Disorders

The pentazocine in VALUELIFE may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during VALUELIFE therapy.

Withdrawal

The use of VALUELIFE, a mixed agonist/antagonist opioid analgesic, in patients who are receiving a full opioid agonist analgesic may reduce the analgesic effect and/or precipitate withdrawal symptoms. Avoid concomitant use of VALUELIFE with a full opioid agonist analgesic. When discontinuing VALUELIFE in a physically-dependent patient, gradually taper the dosage. Do not abruptly discontinue VALUELIFE in these patients.

Risks of Driving and Operating Machinery

VALUELIFE may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of VALUELIFE and know how they will react to the medication.

Tissue Damage at Injection Sites

Severe sclerosis of the skin, subcutaneous tissues, and underlying muscle have occurred at the injection sites of patients who have received multiple doses of pentazocine lactate. Constant rotation of injection sites is, therefore, essential. In addition, animal studies have demonstrated that VALUELIFE is tolerated less well subcutaneously than intramuscularly.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

Muscle Relaxants

<i>Clinical Impact:</i>	Pentazocine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
<i>Intervention:</i>	Monitor patients for signs of respiratory depression that maybe greater Than otherwise expected and decrease the dosage of VALUELIFE and/or the Muscle relaxant as necessary.

Diuretics

<i>Clinical Impact:</i>	Opioids can reduce the efficacy of diuretics by inducing the release of anti diuretic hormone.
<i>Intervention:</i>	Monitor patients for signs of diminished diuresis and/or Effects on blood pressure and increase the dosage of the diuretic as needed.

Anticholinergic Drugs

<i>Clinical Impact:</i>	The concomitant use of anticholinergic drugs may increase risk Of urinary retention and/or severe constipation, which may lead to paralytic ileus.
<i>Intervention:</i>	Monitor patients for signs of urinary retention or reduced gastric motility when VALUELIFE is used concomitantly with anticholinergic

4.6 Fertility, pregnancy and lactation

Risk Summary

Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome.

Available data with VALUELIFE in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.

In animal reproduction studies, pentazocine administered subcutaneously to pregnant hamsters during the early gestational period produced neural tube defects (i.e., exencephaly and cranioschisis) at 4.4 times the maximum daily dose. Based on animal data, advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly.

Labor or Delivery

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. VALUELIFE is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including VALUELIFE, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. Patients receiving VALUELIFE during labor have experienced no adverse effects other

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

Myocardial Infarction

Caution should be exercised in the intravenous use of pentazocine for patients with acute myocardial infarction accompanied by hypertension or left ventricular failure. Data suggest that intravenous administration of pentazocine increases systemic and pulmonary arterial pressure and systemic vascular resistance in patients with acute myocardial infarction.

Impaired Renal or Hepatic Function

Although laboratory tests have not indicated that VALUELIFE causes or increases renal or hepatic impairment, the drug should be administered with caution to patients with such impairment. Extensive Reference ID: 4027790 Page 9 of 18 liver disease appears to predispose to greater side effects (e.g., marked apprehension, anxiety, dizziness, sleepiness) from the usual clinical dose, and may be the result of decreased metabolism of the drug by the liver.

Biliary Surgery

Narcotic drug products are generally considered to elevate biliary tract pressure for varying periods following their administration. Some evidence suggests that pentazocine may differ from other marketed narcotics in this respect (i.e., it causes little or no elevation in biliary tract pressures). The clinical significance of these findings, however, is not yet known.

4.5 Interaction with other medicinal products and other forms of interaction.

Benzodiazepines and other CentralNervous System(CNS) Depressants

<i>Clinical Impact:</i>	Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.
<i>Intervention:</i>	Reserve concomitant prescribing of these drugs for use in patients for Whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs Of respiratory depression and sedation.
<i>Examples:</i>	Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, generalanesthetics, antipsychotics, other opioids, alcohol.

Serotonergic Drugs

<i>Clinical Impact:</i>	The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.
<i>Intervention:</i>	If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue VALUELIFE if serotonin syndrome is suspected.
<i>Examples:</i>	Selective serotoninreuptake inhibitors(SSRIs), serotonin and norepinephrinereuptake inhibitors(SNRIs),tricyclicantidepressants(TCAs),triptans,5-HT3receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g.,mirtazapine, trazodone, tramadol),monoamine oxidase (MAO) inhibitors (thoseintended to treat psychiatric disorders and also others, suchas linezolid

Mixed Agonist/Antagonist and Partial Agonist opioid Analgesics

<i>Clinical Impact:</i>	Mayreduce the analgesic effect of VALUELIFE and/or precipitate withdrawal symptoms.
<i>Intervention:</i>	Avoid concomitant use.
<i>Examples:</i>	Butorphanol, nalbuphine, pentazocine, buprenorphine.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

than those that occur with commonly used analgesics.

Data

Animal Data

In a published report, a single dose of pentazocine administered to pregnant hamsters on Gestation Day 8 increased the incidence of neural tube defects (exencephaly and cranioschisis) at a dose of 196 mg/kg, SC (4.4-times the maximum daily dose (MDD) of 360 mg/day pentazocine on a body surface area basis). No evidence of neural tube defects were reported following a dose of 98 mg/kg (2.2 times the MDD).

Lactation

Risk Summary

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VALUELIFE and any potential adverse effects on the breastfed infant from VALUELIFE or from the underlying maternal condition.

Clinical Considerations

Infants exposed to VALUELIFE through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.

Females and Males of Reproductive Potential

Infertility

Chronic use of opioids may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible.

Pediatric Use

The safety and efficacy of VALUELIFE as preoperative or preanesthetic medication have been established in pediatric patients 1 to 16 years of age. Use of VALUELIFE in these age groups is supported by evidence from adequate and controlled studies in adults with additional data from published controlled trials in pediatric patients. The safety and efficacy of VALUELIFE as a premedication for sedation have not been established in pediatric patients less than one year old. Information on the safety profile of VALUELIFE as a postoperative analgesic in children less than 16 years is limited.

Geriatric Use

Pentazocine is metabolized in the liver and excreted primarily in the urine. Patients with impaired renal or hepatic function may have slower elimination of the drug, and the risk of adverse reactions to this drug may be greater in these patients. Elderly patients (aged 65 years or older) may have increased sensitivity to pentazocine. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were coadministered with other agents that depress respiration. Titrate the dosage of VALUELIFE slowly in geriatric patients and monitor closely for signs of central nervous system and respiratory depression. Pentazocine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

4.7 Effects on ability to drive and use machines

None

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

4.8 Undesirable effects

The following serious adverse reactions are described, or described in greater detail, in other sections:

- Addiction, Abuse, and Misuse
- Life-Threatening Respiratory Depression
- Neonatal Opioid Withdrawal Syndrome
- Interactions with Benzodiazepines or Other CNS Depressants
- Adrenal Insufficiency
- Severe Hypotension
- Gastrointestinal Adverse Reactions
- Seizures
- Withdrawal

The following adverse reactions have been identified during post approval use of pentazocine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most commonly occurring reactions were nausea, dizziness or lightheadedness, vomiting, euphoria. Dermatologic Reactions: Soft tissue induration, nodules, and cutaneous depression can occur at injection sites. Ulceration (sloughing) and severe sclerosis of the skin and subcutaneous tissues (and, rarely, underlying muscle) have been reported after multiple doses. Other reported dermatologic reactions include diaphoresis, sting on injection, flushed skin including plethora, dermatitis including pruritus.

Infrequently occurring reactions are:

Respiratory: respiratory depression, dyspnea, transient apnea in a small number of newborn infants whose mothers received VALUELIFE during labor;

Cardiovascular: circulatory depression, shock, hypertension;

CNS effects: dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, disorientation; infrequently weakness, disturbed dreams, insomnia, syncope, visual blurring and focusing difficulty, depression; and rarely tremor, irritability, excitement, tinnitus;

Gastrointestinal: constipation, dry mouth;

Other: urinary retention, headache, paresthesia, alterations in rate or strength of uterine contractions during labor.

Rarely reported reactions include:

Neuromuscular and psychiatric: muscle tremor, insomnia, disorientation, hallucinations; gastrointestinal: taste alteration, diarrhea and cramps;

Ophthalmic: blurred vision, nystagmus, diplopia, miosis; hematologic: depression of white blood cells (especially granulocytes), which is usually reversible, moderate transient eosinophilia;

Other: tachycardia, weakness or faintness, chills; allergic reactions including edema of the face, toxic epidermal necrolysis.

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use

Anaphylaxis: Anaphylaxis has been reported with ingredients contained in VALUELIFE.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

4.9 Overdose

Clinical Presentation

Acute overdose with VALUELIFE can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

Treatment of Overdose

In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques.

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pentazocine is a mixed agonist-antagonist at opioid receptors. Pentazocine is partial agonist at the mu opioid receptor and an agonist at the kappa opioid receptor.

Effects on the Central Nervous System

Pentazocine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Pentazocine causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Effects on the Gastrointestinal Tract and Other Smooth Muscle

Pentazocine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Effects on the Cardiovascular System

Pentazocine produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.

Effects on the Endocrine System

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon. Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date.

Concentration–Efficacy Relationships

VALUELIFE is a potent analgesic and 30 mg is usually as effective an analgesic as morphine 10 mg or meperidine 75 mg to 100 mg; however, a few studies suggest the VALUELIFE to morphine ratio may range from 20 mg to 40 mg VALUELIFE to 10 mg morphine. The duration of analgesia may sometimes be less than that of morphine. Analgesia usually occurs within 15 to 20 minutes after intramuscular or subcutaneous injection and within 2 to 3 minutes after intravenous injection. VALUELIFE weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. VALUELIFE has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity. The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. The minimum effective analgesic concentration of pentazocine for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance.

Concentration–Adverse Reaction Relationships

There is a relationship between increasing pentazocine plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions.

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

5.2 Pharmacokinetic properties

Pentazocine is metabolized in the liver and excreted primarily in the urine. Clinical data indicate that differences in various pharmacokinetic parameters may be observed with increasing age. In one study, elderly patients exhibited a longer mean elimination half-life, a lower mean total plasma clearance, and a larger mean area under the concentration-time curve than younger patients.

5.3 Preclinical safety data

Carcinogenesis - Long-term animal studies to evaluate the carcinogenic potential of pentazocine have not been conducted. Mutagenesis- Studies to evaluate the mutagenic potential of pentazocine have not been conducted. Impairment of Fertility- Animal studies to evaluate the impact of pentazocine on fertility have not been conducted

Module I Administrative Information

Product name: VALUELIFE (Pentazocine Injection BP 30 mg, 1 mL Ampoule)

6. Pharmaceutical Particulars:

6.1 List of excipients

Benzyl Alcohol, Sodium Chloride, Sodium Hydroxide, Lactic acid & Water for injection.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Do not store above 25°C. Store in the original package. Keep container in the outer carton.

6.5 Nature and contents of container

1 ml clear glass ampoule with blue ring on neck, 10 ampoules packed in carton with pack insert.

6.6 Special precautions for disposal and other handling

Not applicable

7. Marketing Authorization Holder

SANGHARSH LIFECARE PVT LTD

A-503, Solitaire Corporate Park,

Nr. DivyaBhaskar, S.G.Highway,

Makarba, Ahmedabad- 380015.

8. Marketing Authorization Number

Not Applicable.

9. Date of First Authorization/Renewal of the Authorization

Not Applicable.

10. Date of Revision of the Text

Not Applicable.